Abpro Holdings, Inc. (ABP)

Market Cap	11.84M
Revenue (ttm)	183,000
Net Income (ttm)	-21.61M
Shares Out	60.79M
EPS (ttm)	-0.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,327,056
Open	0.1928
Previous Close	0.1979
Day's Range	0.1915 - 0.2139
52-Week Range	0.1516 - 11.1900
Beta	-0.01
Analysts	Strong Buy
Price Target	4.00 (+1,953.39%)
Earnings Date	Aug 18, 2025

About ABP

Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company’s lead product candid...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: ABP
• Website: https://abpro.co

Financial Performance

In 2024, Abpro Holdings's revenue was $183,000, an increase of 50.00% compared to the previous year's $122,000. Losses were -$17.41 million, 48.7% more than in 2023.

Analyst Summary

According to one analyst, the rating for ABP stock is "Strong Buy" and the 12-month stock price target is $4.0.

Price Target

$4.0

(1,953.39% upside)

Analyst Consensus: Strong Buy